Capricor 治疗技术公司寻求林业发展局批准Deramiocel,这是对Duchenne肌肉萎缩性心脏问题可能进行的首次治疗。 Capricor Therapeutics seeks FDA approval for deramiocel, a potential first treatment for Duchenne muscular dystrophy heart issues.

皮治疗公司已向FDA提交了一份生物制品许可申请 (BLA) 关于deramiocel,该细胞疗法旨在治疗杜申肌力发育不良 (DMD) 心肌病. Capricor Therapeutics has submitted a Biologics License Application (BLA) to the FDA for deramiocel, a cell therapy aimed at treating Duchenne muscular dystrophy (DMD) cardiomyopathy. 如果批准,Deramiocel将是这一病症的首例治疗,Capricor将从其伙伴日本新政公司收到1 000万美元的里程碑付款。 If approved, deramiocel would be the first treatment for this condition, and Capricor would receive a $10 million milestone payment from its partner, Nippon Shinyaku. 该疗法已经获得孤儿药品鉴定和其他监管支助。 The therapy has already received Orphan Drug Designation and other regulatory supports.